FDA — authorised 21 December 2004
- Application: NDA021706
- Marketing authorisation holder: SANTARUS
- Local brand name: ZEGERID
- Indication: FOR SUSPENSION — ORAL
- Status: approved
FDA authorised omeprazole/sodium bicarbonate on 21 December 2004 · 232 US adverse-event reports
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Yes. FDA authorised it on 21 December 2004; FDA authorised it on 27 February 2006; FDA authorised it on 24 March 2006.
SANTARUS holds the US marketing authorisation.